DK3279663T3 - Anvendelse af gelsolin til diagnosticering og behandling af inflammationssygdomme - Google Patents

Anvendelse af gelsolin til diagnosticering og behandling af inflammationssygdomme Download PDF

Info

Publication number
DK3279663T3
DK3279663T3 DK17173554.1T DK17173554T DK3279663T3 DK 3279663 T3 DK3279663 T3 DK 3279663T3 DK 17173554 T DK17173554 T DK 17173554T DK 3279663 T3 DK3279663 T3 DK 3279663T3
Authority
DK
Denmark
Prior art keywords
gelsolin
diagnosis
treatment
inflammation diseases
inflammation
Prior art date
Application number
DK17173554.1T
Other languages
English (en)
Inventor
Thomas P Stossel
Andrej Tarkowski
Osborn Anna Charlotta Teresia Magnusson
Original Assignee
Brigham & Womens Hospital Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brigham & Womens Hospital Inc filed Critical Brigham & Womens Hospital Inc
Application granted granted Critical
Publication of DK3279663T3 publication Critical patent/DK3279663T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4712—Muscle proteins, e.g. myosin, actin, protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/104—Lupus erythematosus [SLE]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Rehabilitation Therapy (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
DK17173554.1T 2006-03-15 2007-03-15 Anvendelse af gelsolin til diagnosticering og behandling af inflammationssygdomme DK3279663T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78250806P 2006-03-15 2006-03-15
EP07753102.8A EP2001496B1 (en) 2006-03-15 2007-03-15 Use of gelsolin to diagnose and treat inflammatory diseases

Publications (1)

Publication Number Publication Date
DK3279663T3 true DK3279663T3 (da) 2021-10-18

Family

ID=38522935

Family Applications (2)

Application Number Title Priority Date Filing Date
DK07753102.8T DK2001496T3 (da) 2006-03-15 2007-03-15 Anvendelse af gelsolin til diagnosticering og behandling af inflammationssygdomme
DK17173554.1T DK3279663T3 (da) 2006-03-15 2007-03-15 Anvendelse af gelsolin til diagnosticering og behandling af inflammationssygdomme

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK07753102.8T DK2001496T3 (da) 2006-03-15 2007-03-15 Anvendelse af gelsolin til diagnosticering og behandling af inflammationssygdomme

Country Status (13)

Country Link
US (3) US8198094B2 (da)
EP (2) EP2001496B1 (da)
JP (5) JP5322917B2 (da)
KR (2) KR101556790B1 (da)
CN (2) CN107085113B (da)
AU (1) AU2007227613A1 (da)
CA (1) CA2680413C (da)
DK (2) DK2001496T3 (da)
ES (2) ES2895078T3 (da)
HU (2) HUE035884T2 (da)
PL (2) PL3279663T3 (da)
PT (2) PT2001496T (da)
WO (1) WO2007109056A2 (da)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005046454A2 (en) * 2003-11-12 2005-05-26 Trustrees Of The University Of Pennsylvania Methods of using gelsolin to treat or prevent bacterial sepsis
US9408891B2 (en) 2003-11-12 2016-08-09 The Trustees Of The University Of Pennsylvania Methods of using gelsolin to treat or prevent bacterial sepsis
KR101300929B1 (ko) * 2004-05-12 2013-08-27 더 브리검 앤드 우먼즈 하스피털, 인크. 감염 치료를 위한 겔솔린의 용도
JP4348631B2 (ja) * 2005-03-29 2009-10-21 セイコーエプソン株式会社 半導体素子の製造方法
KR101556790B1 (ko) 2006-03-15 2015-10-01 더 브리검 앤드 우먼즈 하스피털, 인크. 염증성 질환의 진단 및 치료를 위한 겔솔린의 용도
ES2651619T3 (es) * 2006-03-15 2018-01-29 The Brigham And Women's Hospital, Inc. Uso de gelsolina para tratar esclerosis múltiple y diagnosticar enfermedades neurológicas
US7526337B2 (en) * 2006-06-06 2009-04-28 Cardiac Pacemakers, Inc. Method and device for lymphatic system monitoring
US7734341B2 (en) 2006-06-06 2010-06-08 Cardiac Pacemakers, Inc. Method and apparatus for gastrointestinal stimulation via the lymphatic system
US20070282376A1 (en) 2006-06-06 2007-12-06 Shuros Allan C Method and apparatus for neural stimulation via the lymphatic system
US8905999B2 (en) 2006-09-01 2014-12-09 Cardiac Pacemakers, Inc. Method and apparatus for endolymphatic drug delivery
JP2010537625A (ja) * 2007-08-15 2010-12-09 マウントゲイト グループ リミテッド ゲルゾリン結合剤組成物およびその使用
HUE032875T2 (en) * 2008-01-25 2017-11-28 Massachusetts Gen Hospital Diagnostic and therapeutic applications of gelsolin in renal failure
EP2311823A1 (en) * 2009-10-15 2011-04-20 AC Immune S.A. 2,6-Diaminopyridine compounds for treating diseases associated with amyloid proteins or for treating ocular diseases
DE102010026500A1 (de) * 2010-07-07 2012-01-12 Arthrogen Gmbh Verfahren zur Herstellung von autologen Proteinen
RU2677658C2 (ru) * 2012-07-05 2019-01-18 Тайвэн Липосом Ко, Лтд. Способы лечения артрита
KR101416954B1 (ko) * 2012-09-12 2014-07-16 한양대학교 산학협력단 조혈세포 분화 유도 방법
US10161006B2 (en) 2014-03-11 2018-12-25 Iucf-Hyu (Industry-University Cooperation Foundation Hanyang University) Diagnosis of hematologic diseases
WO2016033187A1 (en) * 2014-08-26 2016-03-03 The Brigham And Women's Hospital, Inc. Use of gelsolin in the treatment and diagnosis of sickle cell disease
WO2016040987A1 (en) * 2014-09-15 2016-03-24 Abregen Pty Ltd Treating and/or preventing psoriasis
IT201700083044A1 (it) * 2017-07-20 2019-01-20 Laura Stronati “uso della gelsolina come marcatore diagnostico e prognostico delle malattie infiammatorie intestinali”
US12544422B2 (en) 2019-11-21 2026-02-10 The Regents Of The University Of Michigan Use of gelsolin to treat or prevent lung injury and disease
US11266376B2 (en) 2020-06-19 2022-03-08 Ultrasound Ai Inc. Premature birth prediction
US12369883B2 (en) 2020-06-19 2025-07-29 Ultrasound AI, Inc. Artificial intelligence system for determining clinical values through medical imaging
US20230398176A1 (en) * 2020-09-23 2023-12-14 Bioaegis Therapeutics Inc. Compositions and methods for identifying and treating microparticle-associated diseases and conditions
EP4217374A1 (en) * 2020-09-25 2023-08-02 The Francis Crick Institute Limited Immunotherapy
CN112630430B (zh) * 2020-11-16 2021-08-27 北京美联泰科生物技术有限公司 一种定量检测uchl-1的试剂盒及其应用
KR20250161553A (ko) * 2023-03-13 2025-11-17 울트라사운드 에이아이, 인코포레이티드 의료 이미징을 통한 포괄적인 의료 진단, 예후, 및 치료 최적화를 위한 인공 지능 시스템

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5071773A (en) 1986-10-24 1991-12-10 The Salk Institute For Biological Studies Hormone receptor-related bioassays
CA2016227A1 (en) 1989-05-18 1990-11-18 Xandra O. Breakefield Genetic diagnosis of torsion dystonia
JP3616392B2 (ja) 1990-04-11 2005-02-02 ザ・ブリガム・アンド・ウイメンズ・ホスピタル・インコーポレイテッド アクチン結合性化合物の療法的使用
US5464817A (en) 1990-04-11 1995-11-07 Brigham And Women's Hospital Method for reducing the viscosity of pathological mucoid airway contents in the respiratory tract comprising administering actin-binding compounds with or without DNASE I
CA2063593A1 (en) 1990-05-04 1991-11-05 Biogen, Inc. Multimeric gelsolin fusion constructs
US5571511A (en) 1990-10-22 1996-11-05 The U.S. Government Broadly reactive opsonic antibodies that react with common staphylococcal antigens
AU643141B2 (en) 1991-03-15 1993-11-04 Amgen, Inc. Pulmonary administration of granulocyte colony stimulating factor
US5360350A (en) 1991-08-23 1994-11-01 The Whitaker Corporation Sealant compositions and sealed electrical connectors
WO1994003601A2 (en) 1992-08-03 1994-02-17 New York University Cloning, expression and uses for neurocan as a chondroitin sulfate proteoglycan
US5691160A (en) 1992-08-14 1997-11-25 Biogen, Inc. Effects of actin filaments of fibrin clot structure and lysis
EP0675967A4 (en) 1992-10-01 1999-04-28 Gen Hospital Corp Functional assay for tumor suppressor genes.
US5604260A (en) 1992-12-11 1997-02-18 Merck Frosst Canada Inc. 5-methanesulfonamido-1-indanones as an inhibitor of cyclooxygenase-2
US5543297A (en) 1992-12-22 1996-08-06 Merck Frosst Canada, Inc. Human cyclooxygenase-2 cDNA and assays for evaluating cyclooxygenase-2 activity
US5830436A (en) 1993-03-30 1998-11-03 Duke University Method of mucociliary clearance in cystic fibrosis patients using alkylaryl polyether alcohol polymers
US5474995A (en) 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
GB9602877D0 (en) 1996-02-13 1996-04-10 Merck Frosst Canada Inc 3,4-Diaryl-2-hydroxy-2,5- dihydrofurans as prodrugs to cox-2 inhibitors
US5593964A (en) 1993-10-07 1997-01-14 The George Washington University Medical Center Method of treating septic shock by preventing actin polymerization
JP3914272B2 (ja) 1993-12-28 2007-05-16 中外製薬株式会社 アドゼベリンをコードする遺伝子
HUT74986A (en) 1994-01-10 1997-03-28 Merck Frosst Canada Inc Phenyl heterocycles as cox-2 inhibitors, pharmaceutical preparations containing them, and use of them
AU686780B2 (en) 1994-03-11 1998-02-12 Merck & Co., Inc. Composition for the treatment of lung disease
US5451569A (en) 1994-04-19 1995-09-19 Hong Kong University Of Science And Technology R & D Corporation Limited Pulmonary drug delivery system
US5521213A (en) 1994-08-29 1996-05-28 Merck Frosst Canada, Inc. Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2
JPH10507765A (ja) 1994-10-27 1998-07-28 メルク フロスト カナダ インコーポレーテツド シクロオキシゲナーゼ−２阻害剤として有用なスチルベン誘導体
US5552422A (en) 1995-01-11 1996-09-03 Merck Frosst Canada, Inc. Aryl substituted 5,5 fused aromatic nitrogen compounds as anti-inflammatory agents
US5563153A (en) 1995-02-22 1996-10-08 University Of Kansas Medical Center Sterile topical anesthetic gel
US5846743A (en) 1995-02-22 1998-12-08 Brigham And Women's Hospital, Inc. Polyphoshoinositide binding peptides for intracellular drug delivery
EP0815134B1 (en) 1995-03-14 2002-06-05 Praecis Pharmaceuticals Incorporated Modulators of amyloid aggregation
US5774303A (en) 1995-03-24 1998-06-30 Stormedia, Inc. Sputter induced micro-texturing enhancement for magnetic head structures
US5691374A (en) 1995-05-18 1997-11-25 Merck Frosst Canada Inc. Diaryl-5-oxygenated-2-(5H) -furanones as COX-2 inhibitors
US5804427A (en) 1995-05-19 1998-09-08 University Of Massachusetts Cytokine-, stress-, and oncoprotein-activated human protein kinase kinases
US5604253A (en) 1995-05-22 1997-02-18 Merck Frosst Canada, Inc. N-benzylindol-3-yl propanoic acid derivatives as cyclooxygenase inhibitors
US5639780A (en) 1995-05-22 1997-06-17 Merck Frosst Canada, Inc. N-benzyl indol-3-yl butanoic acid derivatives as cyclooxygenase inhibitors
US5643933A (en) 1995-06-02 1997-07-01 G. D. Searle & Co. Substituted sulfonylphenylheterocycles as cyclooxygenase-2 and 5-lipoxygenase inhibitors
US5925529A (en) 1995-06-07 1999-07-20 The Regents Of The University Of California Method for discovery of peptide agonists
US5569588A (en) 1995-08-09 1996-10-29 The Regents Of The University Of California Methods for drug screening
US5750353A (en) 1995-12-11 1998-05-12 New England Medical Center Hospitals, Inc. Assay for non-peptide agonists to peptide hormone receptors
US5733909A (en) 1996-02-01 1998-03-31 Merck Frosst Canada, Inc. Diphenyl stilbenes as prodrugs to COX-2 inhibitors
US5789413A (en) 1996-02-01 1998-08-04 Merck Frosst Canada, Inc. Alkylated styrenes as prodrugs to COX-2 inhibitors
GB9607503D0 (en) 1996-04-11 1996-06-12 Merck Frosst Canada Inc Bisaryl cyclobutenes derivatives as cyclooxygenase inhibitors
US5922742A (en) 1996-04-23 1999-07-13 Merck Frosst Canada Pyridinyl-2-cyclopenten-1-ones as selective cyclooxygenase-2 inhibitors
US5677318A (en) 1996-07-11 1997-10-14 Merck Frosst Canada, Inc. Diphenyl-1,2-3-thiadiazoles as anti-inflammatory agents
US5861419A (en) 1996-07-18 1999-01-19 Merck Frosst Canad, Inc. Substituted pyridines as selective cyclooxygenase-2 inhibitors
AU3817497A (en) 1996-07-30 1998-02-20 Biogen, Inc. Production of recombinant plasma gelsolin containing a disulfide bond
DE69716460T2 (de) 1996-12-04 2003-06-26 Renovo Ltd., Manchester Wundheilung und behandlung von fibrose
ATE530180T1 (de) * 1997-04-02 2011-11-15 Brigham & Womens Hospital Verfahren zur ermittlung der individualen risikoprofile atherosklerotischen erkrankungen
AU3395900A (en) 1999-03-12 2000-10-04 Human Genome Sciences, Inc. Human lung cancer associated gene sequences and polypeptides
EP1227847A2 (en) 1999-10-06 2002-08-07 Basf Aktiengesellschaft Inhibitors of the endothelin signalling pathway and alphavbeta3 integrin receptor antagonists for combination therapy
WO2002059604A2 (en) * 2001-01-26 2002-08-01 Oxford Glycosciences (Uk) Ltd Diagnosis and treatment of multiple sclerosis
EP1372720A4 (en) 2001-03-02 2006-07-26 Medimmune Inc PREVENTING OR TREATING INFLAMMATORY OR AUTOIMMUNE DISORDERS BY ADMINISTERING ANTAGONISTS OF INTEGRIN ALPHA V BETA 3
EP1249244A1 (en) 2001-04-13 2002-10-16 Universiteit Gent Therapeutic compositions for the treatment of a disease modulated by the G-actin / F-actin equilibrium, especially a respiratory tract disease
EP1414466B1 (en) 2001-07-09 2009-08-19 CombinatoRx, Incorporated Combinations for the treatment of inflammatory disorders
EP1432728A4 (en) 2001-08-30 2007-10-24 Praecis Pharm Inc METHODS AND COMPOSITIONS FOR THE TREATMENT OF INFLAMMATORY DISORDERS
AU2003296875B2 (en) 2002-02-06 2008-01-24 Regenerx Biopharmaceuticals, Inc. Treatment of infections and other disorders
US20080051348A1 (en) 2002-02-06 2008-02-28 Regenerx Biopharmaceuticals, Inc. Treatment of infections and other disorders
WO2003088811A2 (en) * 2002-04-16 2003-10-30 The Brigham And Women's Hospital, Inc. Gelsolin as a prognostic marker of artherosclerotic diseases
AU2003253014A1 (en) 2002-06-21 2004-01-06 Innogenetics N.V. Method for the diagnosis and differential diagnosis of neurological diseases
AU2003289716A1 (en) 2002-09-12 2004-04-30 Incyte Corporation Molecules for diagnostics and therapeutics
KR20050114217A (ko) 2003-02-21 2005-12-05 메드벳 싸이언스 피티와이. 리미티드 진단 및 치료 방법
EP1627076A4 (en) * 2003-03-14 2008-07-02 Ppd Biomarker Discovery Scienc BIOLOGICAL MARKERS FOR THE DIAGNOSIS OF RHEUMATOID ARTHRITIS
GB0327723D0 (en) 2003-09-15 2003-12-31 Vectura Ltd Pharmaceutical compositions
US9408891B2 (en) * 2003-11-12 2016-08-09 The Trustees Of The University Of Pennsylvania Methods of using gelsolin to treat or prevent bacterial sepsis
WO2005046454A2 (en) * 2003-11-12 2005-05-26 Trustrees Of The University Of Pennsylvania Methods of using gelsolin to treat or prevent bacterial sepsis
CA2550833A1 (en) 2003-12-22 2005-07-14 Regenerx Biopharmaceuticals, Inc. Method of treating or preventing biological or immunological responses to a reactive chemical or biological or toxic agent
WO2005085859A1 (en) 2004-02-27 2005-09-15 Roche Diagnostics Gmbh Method of assessing rheumatoid arthritis by measuring rheumatoid factor and interleukin-6
KR101300929B1 (ko) 2004-05-12 2013-08-27 더 브리검 앤드 우먼즈 하스피털, 인크. 감염 치료를 위한 겔솔린의 용도
TW201422238A (zh) 2004-06-04 2014-06-16 Genentech Inc Ｃｄ２０抗體於治療多發性硬化症之用途及用於該用途之物品
US20100062471A1 (en) 2005-09-29 2010-03-11 Ppd Biomarker Discovery Sciences Llc Biomarkers for Multiple Sclerosis and Methods of Use Thereof
ES2651619T3 (es) 2006-03-15 2018-01-29 The Brigham And Women's Hospital, Inc. Uso de gelsolina para tratar esclerosis múltiple y diagnosticar enfermedades neurológicas
KR101556790B1 (ko) 2006-03-15 2015-10-01 더 브리검 앤드 우먼즈 하스피털, 인크. 염증성 질환의 진단 및 치료를 위한 겔솔린의 용도
HUE032875T2 (en) 2008-01-25 2017-11-28 Massachusetts Gen Hospital Diagnostic and therapeutic applications of gelsolin in renal failure
KR101568323B1 (ko) 2014-01-08 2015-11-12 한국원자력의학원 겔솔린을 유효성분으로 포함하는 수지상세포 분화 유도용 조성물 및 이의 분화 유도방법
WO2016033187A1 (en) 2014-08-26 2016-03-03 The Brigham And Women's Hospital, Inc. Use of gelsolin in the treatment and diagnosis of sickle cell disease

Also Published As

Publication number Publication date
EP3279663B1 (en) 2021-07-28
DK2001496T3 (da) 2017-09-18
AU2007227613A1 (en) 2007-09-27
JP6568144B2 (ja) 2019-08-28
EP2001496A4 (en) 2009-07-08
JP2015187163A (ja) 2015-10-29
CN107085113B (zh) 2020-07-17
EP2001496B1 (en) 2017-05-31
PL3279663T3 (pl) 2022-01-10
US20170281724A9 (en) 2017-10-05
CN101443030A (zh) 2009-05-27
EP3279663A1 (en) 2018-02-07
KR20140091048A (ko) 2014-07-18
ES2895078T3 (es) 2022-02-17
CA2680413A1 (en) 2007-09-27
ES2641879T3 (es) 2017-11-14
JP2009530612A (ja) 2009-08-27
US20160228505A1 (en) 2016-08-11
US10238715B2 (en) 2019-03-26
CN107085113A (zh) 2017-08-22
JP2012083359A (ja) 2012-04-26
WO2007109056A3 (en) 2007-12-06
JP2014122924A (ja) 2014-07-03
PT2001496T (pt) 2017-09-08
EP2001496A2 (en) 2008-12-17
US8198094B2 (en) 2012-06-12
US9316639B2 (en) 2016-04-19
WO2007109056A2 (en) 2007-09-27
KR101556790B1 (ko) 2015-10-01
JP5322917B2 (ja) 2013-10-23
PL2001496T3 (pl) 2017-10-31
US20100227807A1 (en) 2010-09-09
HUE035884T2 (en) 2018-05-28
HUE056086T2 (hu) 2022-01-28
JP2017138337A (ja) 2017-08-10
US20120208743A1 (en) 2012-08-16
PT3279663T (pt) 2021-09-24
KR20090004966A (ko) 2009-01-12
JP6198777B2 (ja) 2017-09-20
CA2680413C (en) 2020-06-09
HK1250781A1 (en) 2019-01-11

Similar Documents

Publication Publication Date Title
DK3279663T3 (da) Anvendelse af gelsolin til diagnosticering og behandling af inflammationssygdomme
DK2114419T3 (da) Natriummetaarsenit til anvendelse i behandling af smerte og inflammation
LTC2662091I2 (lt) Anti-p-selektino antikūnai ir jų naudojimo būdai uždegiminių ligų gydymui
DK1889065T3 (da) Metoder til diagnostisering og behandling af sygdomme med en autoimmun- og/eller inflammationskomponent
IL262075B (en) Treatment of inflammatory diseases using placental stem cells
DK1874781T3 (da) Dihydrothienopyrimidiner til behandling af inflammatoriske sygdomme
DK1888033T3 (da) Fremgangsmåde og sammensætning til behandling af inflammatoriske sygdomme
DK1853271T3 (da) Fremgangsmåde og præparat til behandling af perifere vaskulære sygdomme
DK2056807T3 (da) Behandling af inflammatoriske sygdomme
DK2217577T3 (da) Hidtil ukendte forbindelser og præparater og fremgangsmåder til anvendelse deraf
DK2047863T3 (da) Middel til forebyggelse eller behandling af inflammatoriske sygdomme
BRPI0719202A2 (pt) Diagnóstico e tratamento de câncer usando anticorpo antiereg
DK2480574T3 (da) Anti-cd33-antistoffer og deres anvendelse til immunotargeting i behandlingen af cd33-associerede sygdomme
PL2037902T3 (pl) Zastosowanie kanabidiolu w użyciu w leczeniu bólu neuropatycznego
PL2442814T3 (pl) Bifidobacteria do leczenia cukrzycy i pokrewnych chorób
EP1982660A4 (en) TREATMENT ENDOSCOPE
DK1932470T3 (da) Ekg-adaptersystem og fremgangsmåde til anvendelse deraf
DK1755661T3 (da) Gelsolin til anvendelse til behandling af infektioner
DK2018206T3 (da) Bandage til medicinsk anvendelse
DK2056842T3 (da) Modificeret galactosylceramid til behandling af cancerøse sygdomme
DK2004204T3 (da) Behandling af neurodegenerative sygdomme med selenat
DK2099446T3 (da) Fremgangsmåde til behandling af inflammatorisk tarmsygdom
DK1959988T3 (da) Anvendelse af bovint lactoferrin til behandling af destruktiv inflammation af slimhinder
DK2172207T3 (da) Farmaceutisk sammensætning til behandling af diabetes og fremgangsmåde til fremstilling heraf
DK2117565T3 (da) Anvendelse af chitosaner til behandlingen af negleinflammatoriske sygdomme